Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In - Ascendis Pharma ( NASDAQ:ASND )
Tuesday, Ascendis Pharma A/S ASND reported second-quarter sales of $38.76 million ( 35.9 million euros ) , missing the consensus of $92.7 million, down from 47.4 million euros reported a year ago.
| Ticker |
Sentiment |
Impact |
|
BMRN
|
Neutral
|
23 %
|
|
ASND
|
Somewhat Bearish
|
33 %
|
|
NVO
|
Somewhat Bullish
|
23 %
|
|
PFE
|
Somewhat Bullish
|
23 %
|
